mRNA |
thalidomide |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.02 |
mRNA |
crizotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.082 |
0.02 |
mRNA |
UNC0321 |
CTRPv2 |
pan-cancer |
AAC |
0.087 |
0.02 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.077 |
0.02 |
mRNA |
XMD8-92 |
GDSC1000 |
pan-cancer |
AAC |
0.11 |
0.02 |
mRNA |
PD-0325901 |
CCLE |
pan-cancer |
AAC |
-0.097 |
0.02 |
mRNA |
CAL-101 |
CTRPv2 |
pan-cancer |
AAC |
0.083 |
0.02 |
mRNA |
GSK2636771 |
CTRPv2 |
pan-cancer |
AAC |
0.097 |
0.02 |
mRNA |
TL-2-105 |
GDSC1000 |
pan-cancer |
AAC |
-0.073 |
0.03 |
mRNA |
erlotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.084 |
0.03 |